Latest news
Buy Rating Reaffirmed on Lymphir’s Growing Commercial Momentum and CTCL Market Upside; $4 Price Target Maintained - TipRanksTipRanks · Sat, 08 Aug 2026 18:30:19 GMTLYMPHIR orders rise 78% QoQ as Citius Oncology expands market access for CTCL treatment. - pluang.compluang.com · Thu, 06 Aug 2026 08:26:54 GMTCitius Oncology reports strong LYMPHIR U.S. launch momentum - TipRanksTipRanks · Wed, 05 Aug 2026 20:48:45 GMTCitius Oncology reports strong LYMPHIR commercial momentum - TipRanksTipRanks · Wed, 05 Aug 2026 19:33:52 GMTCitius Oncology Reports Strong Commercial Momentum for its Cancer Treatment - PR NewswirePR Newswire · Wed, 05 Aug 2026 13:17:00 GMT